Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside

Author's Avatar
GuruFocus News
08/05/2026 07:37

Starling Oncology Inc STLN is set to release its Q2 2026 earnings on Aug 6, 2026. The consensus estimate for Q2 2026 revenue is 155.19 million, and the earnings are expected to come in at -0.06 per share. The full year 2026's revenue is expected to be $651.94 million and the earnings are expected to be $-0.14 per share. More detailed estimate data can be found on the Forecast page

Starling Oncology Inc STLN Estimates Trends

Revenue estimates for Starling Oncology Inc (STLN) have increased from $647.84 million to $651.94 million for the full year 2026 and increased from $814.80 million to $825.49 million for 2027 over the past 90 days. Earnings estimates for Starling Oncology Inc (STLN) have increased from $-0.23 per share to $-0.14 per share for the full year 2026 and increased from $-0.08 per share to $-0.03 per share for 2027 over the past 90 days.

Starling Oncology Inc STLN Reported History

In the previous quarter of 2026-03-31, Starling Oncology Inc's (STLN) actual revenue was $147.44 million, which beat analysts' revenue expectations of $143.23 million by 2.94%. Starling Oncology Inc's (STLN) actual earnings were $-0.02 per share, which beat analysts' earnings expectations of $-0.08 per share by 74.36%. After releasing the results, Starling Oncology Inc (STLN) was down by -1.72% in one day.

2084983871472050176.png

Starling Oncology Inc STLN 12 Month Price Targets

Based on the one-year price targets offered by 5 analysts, the average target price for Starling Oncology Inc (STLN) is $8.40 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 62.48% from the current price of $5.17.

Based on GuruFocus estimates, the estimated GF Value for Starling Oncology Inc STLN in one year is $2.91, suggesting a downside of -43.71% from the current price of $5.17.

Based on the consensus recommendation from 5 brokerage firms, Starling Oncology Inc's STLN average brokerage recommendation is currently 1.80, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

2084983891101392896.png

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.